Skip to content
Votrient(pazopanib)
Votrient (pazopanib) is a small molecule pharmaceutical. Pazopanib was first approved as Votrient on 2009-10-19. It is used to treat renal cell carcinoma and soft tissue neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 1, vascular endothelial growth factor receptor 3, and vascular endothelial growth factor receptor 2. In addition, it is known to target fibroblast growth factor receptor 1, mast/stem cell growth factor receptor Kit, macrophage colony-stimulating factor 1 receptor, and platelet-derived growth factor receptor beta.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
Votrient
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pazopanib hydrochloride
Tradename
Company
Number
Date
Products
VOTRIENTNovartisN-022465 RX2009-10-19
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
votrientNew Drug Application2020-08-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
renal cell carcinomaEFO_0000376D002292
soft tissue neoplasmsD012983
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pazopanib Hydrochloride, Votrient, Novartis
71055302023-10-19DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
L01EX: Other protein kinase inhibitors in atc
L01EX03: Pazopanib
HCPCS
No data
Clinical
Clinical Trials
261 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD0022921826103964
SarcomaD012509142141236
NeoplasmsD009369C8025611434
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C56612115
Non-small-cell lung carcinomaD00228959114
LeiomyosarcomaD0078902828
OsteosarcomaD0125161415
LiposarcomaD008080515
Lung neoplasmsD008175C34.901314
NeurofibrosarcomaD0183192414
HemangiosarcomaD006394314
Alveolar soft part sarcomaD018234313
Synovial sarcomaD0135841313
Show 8 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C508715
Macular degenerationD008268EFO_0001365H35.30549
Prostatic neoplasmsD011471C61246
Pancreatic neoplasmsD010190EFO_0003860C25346
MelanomaD008545246
GlioblastomaD005909EFO_0000515245
Kidney neoplasmsD007680EFO_0003865C642215
Fallopian tube neoplasmsD005185255
Stomach neoplasmsD013274EFO_0003897C16234
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A44
Show 50 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517933
Head and neck neoplasmsD00625822
Liver neoplasmsD008113EFO_1001513C22.022
SyndromeD01357711
Urogenital neoplasmsD014565EFO_0003863D0711
Papillary thyroid cancerD00007727311
Follicular adenocarcinomaD01826311
NeuroblastomaD009447EFO_000062111
Wilms tumorD00939611
Colonic neoplasmsD003110C1811
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePAZOPANIB
INNpazopanib
Description
Pazopanib is a pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor, a vascular endothelial growth factor receptor antagonist and an angiogenesis modulating agent. It is a member of indazoles, an aminopyrimidine and a sulfonamide. It is a conjugate base of a pazopanib(1+).
Classification
Small molecule
Drug classangiogenesis inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Identifiers
PDB
CAS-ID444731-52-6
RxCUI714438
ChEMBL IDCHEMBL477772
ChEBI ID71219
PubChem CID10113978
DrugBankDB06589
UNII ID7RN5DR86CK (ChemIDplus, GSRS)
Target
Agency Approved
FLT1
FLT1
FLT4
FLT4
KDR
KDR
Organism
Homo sapiens
Gene name
FLT1
Gene synonyms
FLT, FRT, VEGFR1
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 1
Protein synonyms
FLT, FLT-1, fms related tyrosine kinase 1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor
Uniprot ID
Mouse ortholog
Flt1 (14254)
vascular endothelial growth factor receptor 1 (P35969)
Alternate
FGFR1
FGFR1
KIT
KIT
CSF1R
CSF1R
PDGFRB
PDGFRB
Organism
Homo sapiens
Gene name
FGFR1
Gene synonyms
BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR
NCBI Gene ID
Protein name
fibroblast growth factor receptor 1
Protein synonyms
Basic fibroblast growth factor receptor 1, bFGF-R-1, BFGFR, CD331, FGFR1/PLAG1 fusion, FLT-2, FMS-like tyrosine kinase 2, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, N-sam, Proto-oncogene c-Fgr
Uniprot ID
Mouse ortholog
Fgfr1 (14182)
fibroblast growth factor receptor 1 (P16092)
Variants
Clinical Variant
No data
Financial
Votrient - Novartis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 10,695 documents
View more details
Safety
Black-box Warning
Black-box warning for: Votrient
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,240 adverse events reported
View more details